NCT01624662View on ClinicalTrials.gov

Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device

PHASE3CompletedINTERVENTIONAL
Enrollment

323

Participants

Timeline

Start Date

October 30, 2013

Primary Completion Date

May 11, 2015

Study Completion Date

July 3, 2015

Conditions
Bilateral Nasal Polyposis
Interventions
DRUG

Fluticasone propionate

Delivered via Optinose Exhalation Delivery System

Trial Locations (10)

18020

Valley Clinical Research Center, Bethlehem

20902

Institute for Asthma and Allergy, Wheaton

40207

Advanced ENT and Allergy, Louisville

80112

Colorado Allergy & Asthma Centers, PC, Centennial

95207

Bensch Clinical Research LLC, Stockton

97401

Allergy and Asthma Research Group, Eugene

98225

Baker Allergy, Asthma and Dermatology Research Center, LLC, Lake Oswego

Bellingham Asthma, Allergy, and Immunology Clinic, Bellingham

07712

Atlantic Research Center, LLC, Ocean City

05405

University of Vermont, Burlington

All Listed Sponsors
lead

Optinose US Inc.

INDUSTRY

NCT01624662 - Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device | Biotech Hunter | Biotech Hunter